GeoVax takes $1M loan, hands lender control of its board
What's the deal? GeoVax LabsDealroom has a profile for this one. Try Dealroom → (Nasdaq: GOVX), a clinical-stage biotech developing vaccines and immunotherapies, has entered a $1 million unsecured revolving loan agreement with Bowery Consulting Group. The facility, dated October 23, 2026, carries 12% annual interest and matures in 12 months.
The twist: The loan came with sweeping board changes. Five directors resigned, and the lender nominated three replacements — Steven Brown, Tyler O'Brien, and Manpreet Uppal — leaving a five-member board. They serve until the loan is repaid in full.
Why now? GeoVax has repeatedly tapped capital markets this year. It raised roughly $1 million net in a February stock-and-warrant offering and about $2.7 million net in a May private placement, plus cash from warrant exercises.
What's the endgame? The money is working capital. GeoVax's priority program is GEO-MVA, a vaccine targeting mpox and smallpox, with plans to start a pivotal Phase 3 trial in late 2026. It is also developing Gedeptin, a cancer therapy that has completed a Phase 1/2 trial in head and neck cancer.
Chairman and chief executive officer David A. Dodd called the financing "an important achievement," saying it was "reinforcing our balance sheet and providing the working capital needed to support our operations."
What could go wrong? Unlike its recent equity raises, this is debt — at a steep 12% rate, with advances subject to the lender's approval. Ceding three of five board seats to a single lender is an unusual concession for a $1 million facility.
The signal: This is a small, near-term liquidity measure rather than a major financing event. For a company burning cash to advance clinical programs, the loan buys runway — but the board overhaul signals just how tight GeoVax's options have become.
Read more: newmediawire.com
Image credit: IAPEN Activities
